entertainment -WSS

entertainment

author：explore 2025-08-23 05:02:18 - browse：228

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： YouTube cracks down on misinformation on cancer treatment

focus

WSS

Aspartame and sugar

Indictment alleges Trump's ex

Be careful with at

Timeline: How the deadly wildfires took over Maui day by day

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Wikipedia

entertainment

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Timeline: How the deadly wildfires took over Maui day by day

Hepatitis C has a cure — but many Americans still lack access to it

Mark Cuban is blaming the wrong people for high drug costs

Medical leaders decry Supreme Court decision on affirmative action

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Moonlake's readout produced a cash windfall. Risks remain

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Jerome Adams on the need for new antivirals for Covid

Patients, digital health players weigh in on FTC's data privacy plan

hotspot

After Optum profits sink, UnitedHealth makes changes

Biogen’s boardroom scandal saddles CEO with first crisis

Home health providers sue Medicare over payment cuts

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

YouTube cracks down on misinformation on cancer treatment

The aspartame in Diet Coke probably isn’t giving you cancer

focus

knowledge

knowledge

knowledge